STOCK TITAN

Enlivex Ltd. (ENLV) Stock News, Mar-Jun 2024

ENLV NASDAQ

Enlivex Ltd. develops quality longevity therapeutics and operates a prediction markets treasury alongside its clinical programs. The company’s news centers on Allocetra™, a clinical-stage immunotherapy for inflammatory conditions associated with aging, with a primary focus on moderate-to-severe age-related knee osteoarthritis.

Recurring updates also cover the RAIN token and Rain protocol, including digital asset treasury holdings, exchange listings, decentralized prediction-market infrastructure, tokenized exposure to Enlivex ordinary shares, financial results affected by treasury assets, financing activity, and share repurchase authorization.

Rhea-AI Summary

Enlivex Therapeutics released positive interim data from a Phase I/II trial of AllocetraTM for end-stage knee osteoarthritis. The trial involved nine patients who received a single injection of AllocetraTM. At three months, the results showed a 64% average reduction in pain, with 33% of patients experiencing complete pain relief. Notably, 89% of patients avoided knee replacement surgery. No severe adverse events were reported. The trial continues to recruit with a goal of 18 patients, assessing safety and pain relief up to 12 months post-injection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.79%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) has received regulatory approval from the Israeli Ministry of Health to initiate a Phase I/II trial of Allocetra™ for thumb osteoarthritis. This is the first study of Allocetra™ in thumb osteoarthritis, following previous studies in knee osteoarthritis. The trial will be led by Dr. Amir Oron and aims to evaluate the safety, efficacy, and tolerability of Allocetra™ in up to 46 patients who have failed conventional therapies. The trial consists of two stages: an open-label dose escalation phase and a double-blind, placebo-controlled phase. The primary endpoints will measure safety and efficacy over 12 months. Enlivex aims to expand its osteoarthritis clinical programs into additional joints.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.09%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics announced the closing of a $15 million registered direct offering. This includes the sale of 3,571,429 ordinary shares and warrants to a single healthcare-focused institutional investor at $1.40 per share. The gross proceeds amount to $5.0 million initially, with potential additional proceeds of $10.0 million if the warrants are fully exercised. The funds will be used for working capital and corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The Series A and B warrants have specific expiration terms based on clinical milestone achievements of Enlivex's Allocetra™ for knee osteoarthritis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.05%
Tags
Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) announced a $15 million registered direct offering with a healthcare-focused institutional investor.

The deal includes $5 million upfront for 3,571,429 ordinary shares at $1.40 per share and associated clinical milestone-linked warrants. The Series A warrants expire 18 months after issuance or 60 days post-publication of positive topline results from the ENX-CL-05-001 trial for Allocetra in knee osteoarthritis. Series B warrants expire 5.5 years after issuance or 60 days post-FDA filing for Allocetra's osteoarthritis indication.

Gross proceeds could total $10 million if all warrants are exercised. The offering closes around May 29, 2024, with H.C. Wainwright & Co. as the placement agent.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
-
Rhea-AI Summary

Enlivex Therapeutics (Nasdaq: ENLV) CEO, Oren Hershkovitz, updates shareholders on the progress of AllocetraTM, a macrophage reprogramming immunotherapy drug. The company released positive top-line data from a Phase II trial in patients with sepsis and demonstrated the potential effectiveness of AllocetraTM in high-risk urinary tract infection patients, along with a favorable safety profile. Enlivex sees a significant market opportunity in sepsis and osteoarthritis, believing each segment could represent a multi-billion dollar commercial chance. The company also began a Phase I/II trial for knee osteoarthritis patients. Enlivex is optimistic about the future impact of AllocetraTM and the potential to revolutionize medical treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.02%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none

FAQ

What is the current stock price of Enlivex (ENLV)?

Enlivex (ENLV) last closed at $1.19.

What is the market cap of Enlivex (ENLV)?

The market cap of Enlivex (ENLV) is approximately $1.8M.